Waldencast

WALD

Market cap $251M

A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair* A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair*

U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market

Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand's Addressable Market in the U.S.

Waldencast plc WALD will release earnings results for the second quarter after the closing bell on Monday, Aug. 18.

Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid (HA) injectable gels. The strategic acquisition expands Obagi Medical's offerings beyond U.S. medical-grade skincare, a market projected to be $2.2 billion by 2029, into the growing U.S. dermal filler market, projected to reach $2 billion in market size by 2029, effectively doubling its addressable market.1 The move marks a pivotal step in positioning Obagi Medical as an industry leader in integrated skincare and aesthetic solutions.

Waldencast is a fast-growing beauty company with strong brands (Milk Makeup, Obagi), but faces margin pressure and negative earnings due to high SG&A and debt. Recent revenue growth remains solid, but Q1 FY25 saw a sales dip, especially in Milk Makeup, due to international headwinds and inventory adjustments. The company's financials are typical for a high-growth firm: negative cash flow, high leverage, but manageable liquidity, and a long debt runway until 2030.

Waldencast plc (NASDAQ:WALD ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Allison Malkin - Partner ICR, Investor Relations Michel Brousset - Founder & Chief Executive Officer Manuel Manfredi - Chief Financial Officer Conference Call Participants John Chapman - Alliance Global Partners Jonna Kim - TD Cowen Operator Good day, and welcome to the Waldencast First Quarter 2025 Earnings Call. All participants will be in listen-only mode.

Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4 million of Adjusted EBITDA

LONDON, May 06, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its First Quarter Fiscal 2025 conference call and webcast. As previously announced, the Company will issue its First Quarter Fiscal 2025 results on May 13, 2025 after the close of the U.S. market.

A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion